BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38394685)

  • 1. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.
    Aguilar EN; Sagar S; Murray BR; Rajesh C; Lei EK; Michaud SA; Goodlett DR; Caffrey TC; Grandgenett PM; Swanson B; Brooks TM; Black AR; van Faassen H; Hussack G; Henry KA; Hollingsworth MA; Brooks CL; Radhakrishnan P
    Mol Cancer Ther; 2024 Feb; ():. PubMed ID: 38394685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
    Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.
    Mack KN; Samuels ZV; Carter LM; Viray TD; Mandleywala K; Brooks CL; Hollingsworth MA; Radhakrishnan P; Lewis JS
    J Nucl Med; 2024 Apr; 65(4):580-585. PubMed ID: 38485271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer.
    Olson MT; Aguilar EN; Brooks CL; Isder CC; Muilenburg KM; Talmon GA; Ly QP; Carlson MA; Hollingsworth MA; Mohs AM
    Mol Pharm; 2022 Oct; 19(10):3586-3599. PubMed ID: 35640060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
    Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
    Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker.
    White B; Patterson M; Karnwal S; Brooks CL
    Proteins; 2022 May; 90(5):1210-1218. PubMed ID: 35037700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism.
    Muniyan S; Haridas D; Chugh S; Rachagani S; Lakshmanan I; Gupta S; Seshacharyulu P; Smith LM; Ponnusamy MP; Batra SK
    Genes Cancer; 2016 Mar; 7(3-4):110-124. PubMed ID: 27382435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion.
    Marimuthu S; Lakshmanan I; Muniyan S; Gautam SK; Nimmakayala RK; Rauth S; Atri P; Shah A; Bhyravbhatla N; Mallya K; Grandgenett PM; Hollingsworth MA; Datta K; Jain M; Ponnusamy MP; Batra SK
    Mol Cancer Res; 2022 Aug; 20(8):1208-1221. PubMed ID: 35533267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.
    Shimizu A; Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Kitahata Y; Nakamura Y; Noda T; Yokoyama S; Yamaue H
    Cancer Sci; 2012 Apr; 103(4):739-46. PubMed ID: 22320398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling.
    Rajesh C; Sagar S; Rathinavel AK; Chemparathy DT; Peng XL; Yeh JJ; Hollingsworth MA; Radhakrishnan P
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for antibody recognition of the proximal MUC16 ectodomain.
    Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
    J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent.
    Babeker H; Ketchemen JP; Annan Sudarsan A; Andrahennadi S; Tikum AF; Nambisan AK; Fonge H; Uppalapati M
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
    Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
    Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies.
    Shah A; Chaudhary S; Lakshmanan I; Aithal A; Kisling SG; Sorrell C; Marimuthu S; Gautam SK; Rauth S; Kshirsagar P; Cox JL; Natarajan G; Bhatia R; Mallya K; Rachagani S; Nasser MW; Ganti AK; Salgia R; Kumar S; Jain M; Ponnusamy MP; Batra SK
    NPJ Precis Oncol; 2023 Aug; 7(1):74. PubMed ID: 37567918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.
    Lakshmanan I; Marimuthu S; Chaudhary S; Seshacharyulu P; Rachagani S; Muniyan S; Chirravuri-Venkata R; Atri P; Rauth S; Nimmakayala RK; Siddiqui JA; Gautam SK; Shah A; Natarajan G; Parte S; Bhyravbhatla N; Mallya K; Haridas D; Talmon GA; Smith LM; Kumar S; Ganti AK; Jain M; Ponnusamy MP; Batra SK
    Oncogene; 2022 Nov; 41(48):5147-5159. PubMed ID: 36271032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.
    Xiang X; Feng M; Felder M; Connor JP; Man YG; Patankar MS; Ho M
    J Cancer; 2011; 2():280-91. PubMed ID: 21611109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16.
    Duraisamy S; Ramasamy S; Kharbanda S; Kufe D
    Gene; 2006 May; 373():28-34. PubMed ID: 16500040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
    Stasenko M; Smith E; Yeku O; Park KJ; Laster I; Lee K; Walderich S; Spriggs E; Rueda B; Weigelt B; Zamarin D; Rao TD; Spriggs DR
    Sci Rep; 2021 Feb; 11(1):3718. PubMed ID: 33580170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer.
    Olson MT; Wojtynek NE; Talmon GA; Caffrey TC; Radhakrishnan P; Ly QP; Hollingsworth MA; Mohs AM
    Mol Cancer Ther; 2020 Aug; 19(8):1670-1681. PubMed ID: 32404409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.
    Argüeso P; Spurr-Michaud S; Russo CL; Tisdale A; Gipson IK
    Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2487-95. PubMed ID: 12766047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.